Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

Hamid Emamekhoo,Mark R. Olsen,Bradley Curtis Carthon,Alexandra Drakaki,Ivor John Percent,Ana M. Molina,Daniel C. Cho,Johanna C. Bendell,Lucio N. Gordan,Arash Rezazadeh Kalebasty,Daniel J. George,Thomas E. Hutson,Richard Lee,Tina C. Young,Jennifer Johansen,Scott S. Tykodi

Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

2019

Hamid Emamekhoo
Mark R. Olsen
Bradley Curtis Carthon
Alexandra Drakaki
Ivor John Percent
Ana M. Molina
Daniel C. Cho
Johanna C. Bendell
Lucio N. Gordan
Arash Rezazadeh Kalebasty
Daniel J. George
Thomas E. Hutson
Richard Lee
Tina C. Young
Jennifer Johansen
Scott S. Tykodi

4517Background: Previous clinical trials of patients (pts) with aRCC, including CheckMate 214, have mostly excluded pts with brain metastases. However, antitumor activity in pts with brain metastas...

Keywords:

Ipilimumab
Nivolumab
Renal cell carcinoma
Interim analysis
Oncology
Pathology
Internal medicine
Checkmate
Medicine
in patient
antitumor activity
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations